Pulmonx (LUNG) Stock
What Pulmonx's price implies, from its SEC filings.
Key numbers
- P/E (forward)
- -3.05x
- Revenue growth
- -3.1%
- Operating margin
- -44.4%
- Debt / equity
- 1.11x
What Pulmonx's price implies
Pulmonx's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.
Revenue and free cash flow
Fiscal years, from Pulmonx's 10-K filings.
Pulmonx revenue and free cash flow
FY2018–FY2025Results from SEC filings
All three statements · Quarters, TTM and 20+ years of statements in Investingly
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $48M | $54M | $69M | $84M | $90M |
| Net income | -$49M | -$59M | -$61M | -$56M | -$54M |
| Free cash flow | -$45M | -$46M | -$38M | -$33M | -$33M |
| EPS (diluted) | -$1.35 | -$1.59 | -$1.60 | -$1.44 | -$1.33 |
| Operating margin | -97.7% | -109.3% | -90.2% | -68.9% | -59.3% |
Where the revenue comes from
By regions, fiscal 2025. By year
Superinvestors who own LUNG
From each investor's latest 13F filing (what a 13F shows). All 8 holders
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| PRIMECAP Management PRIMECAP Management Co | Trimmed | $6M | 0.00% | Q2 2026 |
| Acadian Acadian Asset Management | Added | $997,000 | 0.00% | Q3 2026 |
| Cliff Asness AQR Capital Management | Added | $968,453 | 0.0% | Q2 2026 |
| Jim Simons Renaissance Technologies | Added | $552,643 | 0.00% | Q2 2026 |
| David Shaw D. E. Shaw & Co. | Trimmed | $425,787 | 0.0% | Q2 2026 |
| Paul Marshall Marshall Wace | New position | $299,959 | 0.0% | Q2 2026 |
| Two Sigma Two Sigma Investments | Added | $112,548 | 0.0% | Q2 2026 |
| Paul Tudor Jones Tudor Investment Corp | Held | $14,336 | 0.0% | Q2 2026 |
Pulmonx insider buying
Open-market purchases by executives and directors in the last 12 months, from SEC Form 4 filings (what insider buying tells you).
No open-market insider purchases of LUNG in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.
Fundamental grade
Five factors scored 1 to 9 from LUNG's latest numbers. It describes the business, not whether the stock is a buy.
Get an alert at your buy price
Free accounts get 3 price alerts.
How Pulmonx compares
Pulmonx's revenue growth is higher than 23% of Healthcare companies and 16% of the 3,491 companies with a revenue growth figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| Revenue growth | 23% | 16% |
| Operating margin | 30% | 11% |
| ROE | 8% | 3% |
Questions about Pulmonx
Are Pulmonx insiders buying the stock?
No open-market insider purchases of LUNG in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own Pulmonx?
8 of the superinvestors Investingly tracks hold LUNG in their latest 13F, including PRIMECAP Management, Acadian, Cliff Asness.
Prices and ratios as of Nov 9, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.